Literature DB >> 18838215

Synthesis and anti-cancer activity of covalent conjugates of artemisinin and a transferrin-receptor targeting peptide.

Steve Oh1, Byung Ju Kim, Narendra P Singh, Henry Lai, Tomikazu Sasaki.   

Abstract

Artemisinin, a natural product isolated from Artemisia annua L., shows a unique anti-cancer activity by an iron dependent mechanism. Artemisinin was covalently conjugated to a transferrin-receptor targeting peptide, HAIYPRH that binds to a cavity on the surface of transferrin receptor. This enables artemisinin to be co-internalized with receptor-bound transferrin. The iron released from transferrin can activate artemisinin to generate toxic radical species to kill cells. The artemisinin-peptide conjugates showed potent anti-cancer activity against Molt-4 leukemia cells with a significantly improved cancer/normal cells selectivity.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18838215     DOI： 10.1016/j.canlet.2008.08.031

Source DB:  PubMed          Journal:  Cancer Lett        ISSN： 0304-3835            Impact factor:   8.679


  32 in total

1.  Design, synthesis, and study of a mycobactin-artemisinin conjugate that has selective and potent activity against tuberculosis and malaria.

Authors:  Marvin J Miller; Andrew J Walz; Helen Zhu; Chunrui Wu; Garrett Moraski; Ute Möllmann; Esther M Tristani; Alvin L Crumbliss; Michael T Ferdig; Lisa Checkley; Rachel L Edwards; Helena I Boshoff
Journal:  J Am Chem Soc       Date:  2011-01-28       Impact factor: 15.419

2.  In vitro and initial in vivo evaluation of (68)Ga-labeled transferrin receptor (TfR) binding peptides as potential carriers for enhanced drug transport into TfR expressing cells.

Authors:  Carmen Wängler; Dina Nada; Georg Höfner; Simone Maschauer; Björn Wängler; Stephan Schneider; Esther Schirrmacher; Klaus T Wanner; Ralf Schirrmacher; Olaf Prante
Journal:  Mol Imaging Biol       Date:  2011-04       Impact factor: 3.488

3.  Preparation and investigation of bioactive transferrin-iron complexes formed with different synergistic anions.

Authors:  Judit Gálicza; Andrea Vargová; Viktor Sándor; Csongor Kálmán Orbán; Csaba Dezso András; Beáta Abrahám; Szabolcs Lányi; Ferenc Kilár
Journal:  Protein J       Date:  2012-01       Impact factor: 2.371

Review 4.  Development of artemisinin compounds for cancer treatment.

Authors:  Henry C Lai; Narendra P Singh; Tomikazu Sasaki
Journal:  Invest New Drugs       Date:  2012-08-31       Impact factor: 3.850

Review 5.  The transferrin receptor and the targeted delivery of therapeutic agents against cancer.

Authors:  Tracy R Daniels; Ezequiel Bernabeu; José A Rodríguez; Shabnum Patel; Maggie Kozman; Diego A Chiappetta; Eggehard Holler; Julia Y Ljubimova; Gustavo Helguera; Manuel L Penichet
Journal:  Biochim Biophys Acta       Date:  2011-08-05

Review 6.  Intelligent design of multifunctional lipid-coated nanoparticle platforms for cancer therapy.

Authors:  Srinivas Ramishetti; Leaf Huang
Journal:  Ther Deliv       Date:  2012-12

Review 7.  Redox-directed cancer therapeutics: molecular mechanisms and opportunities.

Authors:  Georg T Wondrak
Journal:  Antioxid Redox Signal       Date:  2009-12       Impact factor: 8.401

Review 8.  Co-opting biology to deliver drugs.

Authors:  Parisa Yousefpour; Ashutosh Chilkoti
Journal:  Biotechnol Bioeng       Date:  2014-07-21       Impact factor: 4.530

Review 9.  Polymer-mediated gene therapy: Recent advances and merging of delivery techniques.

Authors:  Janelle W Salameh; Le Zhou; Sarah M Ward; Cristiam F Santa Chalarca; Todd Emrick; Marxa L Figueiredo
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2019-12-02

10.  Artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria.

Authors:  Stephan Ehrhardt; Christian G Meyer
Journal:  Ther Clin Risk Manag       Date:  2009-10-12       Impact factor: 2.423
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.